Ahmedabad, Gujarat, India, April 2025 – Sarang Pande has joined Intas Pharmaceuticals as Vice President – Digital Manufacturing & Industry Automation, bringing with him over 17 years of deep expertise in pharmaceutical manufacturing, digital transformation, process excellence, and industrial automation. In his new role, Sarang will lead digitalization initiatives across Intas’ manufacturing operations, spearheading efforts in Industry 4.0, automation, and data-driven process optimization to support the company’s aggressive global growth goals.
Prior to joining Intas, Sarang Pande was with Dr. Reddy’s Laboratories for over nine years, where he played several key roles including Head – Digital Transformation Office (OpsNEXT) and Head – Digital Transformation & Process Excellence for OSD operations. During his tenure, he led value delivery across manufacturing sites, drove analytics adoption, created GxP-compliant big data infrastructure, and successfully implemented machine learning models to improve solvent recovery and yield.
At Reliance Industries, Sarang worked as General Manager – Strategy & Planning for the petrochemical business, driving strategic planning and project execution for API scale-ups and circular economy initiatives. He also completed a transformative academic stint as a PGPEX-VLM student at IIM Calcutta, part of a premier tri-institute program in collaboration with IIT Kanpur, IIT Madras, and JICA, aimed at developing techno-managerial leaders.
Earlier in his career, Sarang held impactful roles at leading pharmaceutical companies including Cipla, Sandoz, Piramal Enterprises, and Pfizer, where he contributed significantly to API manufacturing, scale-up, solvent recovery, and data integrity process improvement.
About Intas Pharmaceuticals
Intas Pharmaceuticals is a globally recognized leader in pharmaceutical formulation development, manufacturing, and marketing, achieving over $2.5 billion in revenue and maintaining a 19% CAGR. Present in 85+ countries, Intas generates over 70% of its business from international markets under the Accord Healthcare brand.
As the largest privately held Indian generics company, Intas leads in therapeutic areas like CNS, cardiology, oncology, and urology, and is among the top 10 generic players in regulated markets such as the EU, US, and UK. The company operates 17 facilities globally, accredited by major regulators including USFDA, EMA, and MHRA, and employs over 23,000 professionals.
With a robust investment in R&D and a mission to deliver “Biosimilars for Billions”, Intas is at the forefront of affordable and innovative biologics and plasma-derived therapeutics, anchored by a values-driven culture focused on innovation, ownership, performance, and care for society.
Read Also : HR Is Not a Support Function—It’s the CEO’s Most Powerful Growth Engine
The Fine Balance: Navigating Work, Life, and Mental Wellbeing
From Gatekeeping to Gateway Building: Transforming How Organisations Create Access
Leadership In Talent Management: A Powerful Driver for Economic Growth
